Therapeutic progress in lung squamous cell carcinoma has lagged, with recent antiangiogenic–checkpoint inhibitor combinations failing primary endpoints despite improved safety, underscoring unmet need ...
As artificial intelligence (AI) tools continue to proliferate, they are becoming a go-to search tool for patients, providers, and caregivers. Blood cancer patients are using AI in oncology to help ...
The Inflation Reduction Act introduced Medicare drug price negotiations to reduce treatment costs, enhance access, and potentially reshape prescribing patterns in oncology and hematology.
Experts agree that combination approaches, which may or may not include chemotherapy, will drive improved patient outcomes in oncology.
After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.
CLL is the most common type of leukemia in adults. 3 An estimated 18,500 people were treated for CLL in the 1st-line setting in the US in 2024. 4 Jennifer Brown, MD, PhD, Director of the CLL Center of ...
Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...
Experts explore the evolving landscape of chronic lymphocytic leukemia treatment, highlighting targeted therapies, MRD strategies, and future innovations. In this episode of Treating Together, host ...
At issue was a 60-second DTC TV ad promoting BeOne’s BTK inhibitor Brukinsa. The letter from the FDA’s Office of Prescription Drug Promotion – mislabeled as a close-out letter — was issued on January ...
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and represents a significant proportion of leukemias diagnosed in the Western countries but the true incidence and relative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results